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Ro25-6981GluN2B subunit containing NMDARs (GluN2B-NMDARs) mediate pathophysiological effects of acutely applied
amyloid beta (Aβ), including impaired long-term potentiation (LTP). However, in transgenic Alzheimer's disease
(AD) mouse models which feature gradual Aβ accumulation, the function of GluN2B-NMDARs and their contri-
bution to synaptic plasticity are unknown. Therefore, we examined the role of GluN2B-NMDARs in synaptic func-
tion and plasticity in the hippocampus of PS2APP transgenic mice. Although LTP induced by theta burst
stimulation (TBS) was normal in PS2APP mice, it was signiﬁcantly reduced by the selective GluN2B-NMDAR
antagonist Ro25-6981 (Ro25) in PS2APP mice, but not wild type (wt) mice. While NMDARs activated by single
synaptic stimuli were not blocked by Ro25, NMDARs recruited during burst stimulation showed larger blockade
by Ro25 in PS2APPmice. Thus, the unusual dependence of LTP on GluN2B-NMDARs in PS2APPmice suggests that
non-synaptic GluN2B-NMDARs are activated by glutamate that spills out of synaptic cleft during the burst
stimulation used to induce LTP. While long-term depression (LTD) was normal in PS2APP mice, and Ro25 had
no impact on LTD in wt mice, Ro25 impaired LTD in PS2APP mice, again demonstrating aberrant GluN2B-
NMDAR function during plasticity. Together these results demonstrate altered GluN2B-NMDAR function in a
model of early AD pathology that has implications for the therapeutic targeting of NMDARs in AD.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Amyloid beta (Aβ), the major constituent of the hallmark plaques
found in AD patients' brains, plays a causative role in AD: Mutations in
the amyloid precursor protein (APP) or the secretases that cleave APP
that result in elevated Aβ levels cause dominantly inherited AD (St
George-Hyslop, 2000), while APP mutations that reduce Aβ production
confer a decreased risk for sporadic AD (Jonsson et al., 2012). At the
same time, the failure of clinical trials aimed at reducing Aβ burden in
the later stages of AD hasmotivated current therapeutic efforts to inter-
vene early in disease progression, before irreversible neuronal loss has
occurred (Aisen et al., 2013; Callaway, 2012). Multiple lines of evidence
suggest that the deleterious effects of Aβ prior to neuronal loss can be
mediated by NMDARs, especially GluN2B-NMDARs. First, impairmentSan Francisco, CA 94080, USA.
), zhouqiang@PKUSZ.edu.cn
ect.com).
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. This is an open access article underof LTP by acute application of exogenous Aβ is mitigated or prevented
by antagonists that are selective for GluN2B-NMDARs (Li et al., 2011;
Olsen and Sheng, 2012; Rammes et al., 2011; Ronicke et al., 2011). Sec-
ond, GluN2B-NMDAR antagonists prevent the synapse loss induced by
incubation with exogenous Aβ (Ronicke et al., 2011). Third, GluN2B-
NMDAR antagonists can also block other effects of exogenous Aβ appli-
cation to neurons including disruption of intracellular calcium homeo-
stasis (Ferreira et al., 2012) and endoplasmic reticulum oxidative
stress (Costa et al., 2012). Furthermore, a signiﬁcant amount of
GluN2B-NMDARs are located in extrasynaptic regions of adult excitato-
ry neurons (Hanson et al., 2013; Papouin et al., 2012). Consistent with
the idea that blocking extrasynaptic NMDARs could be beneﬁcial for
AD, memantine, an NMDAR antagonist approved for the treatment of
AD, preferentially inhibits extrasynaptic NMDARs (Xia et al., 2010),
suggesting that the beneﬁt of memantine in AD could involve blockade
of extrasynaptic GluN2B-NMDARs.
To our knowledge, all previous studies of the effects of GluN2B
antagonists on synaptic plasticity in the context of AD have exclusively
relied on acute application of high concentrations of Aβ. In contrast, the
gradual accumulation of Aβ that occurs in AD could have very distinct
effects from those observed with acute application. To determine the
impact of gradual Aβ accumulation on GluN2B-NMDAR function inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
255J.E. Hanson et al. / Neurobiology of Disease 74 (2015) 254–262synaptic transmission and plasticity, we used the PS2APP mouse model
of AD that expresses both APP (Swedish mutation) and presenilin 2
(N141I mutation) transgenes, and accumulates Aβ starting at an early
age (Ozmen et al., 2009; Richards et al., 2003). GluN2B NMDARs
were blocked using Ro25, an antagonist that can be used to block di-
heteromeric GluN1/GluN2B/GluN2B NMDARs with little effect on
di-heteromeric GluN1/GluN2A/GluN2A or tri-heteromeric GluN1/
GluN2A/GluN2B NMDARs (Hansen et al., 2014; Hatton and Paoletti,
2005).
We found that while the magnitude of synaptic plasticity was
normal in PS2APP mice, Ro25 resulted in partial impairment of LTP
and LTD in PS2APP mice, despite not affecting wt synaptic plasticity.
This unusual reliance of LTP and LTD on GluN2B-NMDARs appears to
bemediated by a pool of non-synaptic NMDARs that are activated selec-
tively during burst stimulation. We also observed evidence of other
abnormalities in GluN2B-NMDAR function which could include presyn-
aptic alterations. The unexpected contribution of GluN2B-NMDARs to
synaptic function at an early stage of pathology in PS2APPmice provides
new insights regarding potential pharmacological manipulation of
NMDARs in the treatment of AD.
Methods
Ethics statement
All animal experiments were conducted in accordance with the
National Institute of Health Guide for the Care and Use of Laboratory
Animals and were approved by the Genentech Institutional Animal
Care and Use Committee.
Animals
Twelve to 16 week old male mice homozygous for the PS2APP
transgenes and their wt littermate controls were used (Ozmen et al.,
2009; Richards et al., 2003). All experiments were approved by the
Genentech IUCAC and conducted in accordance with the NIH Guide
for the Care and Use of Laboratory Animals.
Drugs
Brain slice experiments used: 3 μM Ro25-6981, 50 μM D-(−)-2-
amino-5-phosphonopentanoic acid (AP5), 20 μMMK-801 (Dizocilpine),
10 μM 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-
dione (NBQX) disodium salt, and 100 μM Picrotoxin (PTX) from Tocris.
Brain slices
400 μm horizontal slices containing hippocampus were prepared
with a vibrating sectioning system (Leica, Germany) andwere recorded
in oxygenated artiﬁcial cerebrospinal ﬂuid (ACSF) containing (in mM)
127 NaCl, 2.5 KCl, 1.3 MgSO4, 2.5 CaCl2, 1.25 Na2HPO4, 25 NaHCO3 and
25 glucose. Slices were prepared in ice-cold oxygenated ACSF with the
MgSO4 concentration elevated to 7 mM, NaCl replaced with 110 mM
choline and with 11.6 mM Na-ascorbate and 3.1 mM Na-pyruvate.
Field recordings
Excitatory postsynaptic potentials (EPSPs) were measured from the
stratum radiatumof CA1 in response to stimulation of Schaffer collateral
inputs. NMDAR EPSPs were measured with the Mg2+ concentration in
ACSF reduced to 0.5 mM and in the presence of PTX and NBQX. LTP
was induced using 1, 2 or 3 bouts of theta burst stimulation (TBS) sep-
arated by 20 s, each bout consisting of 5 pulses at 100 Hz repeated 10
times at 200 ms intervals. The subthreshold LTD induction protocol
used 15 min of 1 Hz stimulation with 200 ms interval paired stimuli in
the presence of normal ACSF. Effective LTD was induced in adult slicesusing 10 min of 1 Hz stimulation with the Ca2+ concentration in ACSF
increased to 4 mM. Ro25 was applied to brain slices for N30 min prior
to inducing LTP or LTD. All experiments with Ro25 vs. vehicle treatment
ofwt and PS2APPmicewere analyzed using two-factor ANOVAs follow-
ed by assessmentwith Holm–Sidak tests. Comparisons of phenotypes in
PS2APP mice vs. wt mice in experiments with no drug treatment were
performed using a Student's t-test.
Western blot analysis
Western blot analysis of NMDAR subunits was performed as de-
scribed previously (Hanson et al., 2013). Antibodies were used at the
following dilutions: anti-NMDAR1 (1:1000; Abcam); anti-NMDAR2A
(1:1000; Novus Biologicals); anti-NMDAR2B (1:1000; NeuroMab);
and anti-β-actin (1:2000; Cell Signaling Technology). The expression
of the target protein and the corresponding internal control (β-actin)
were measured by quantifying the total intensity of enhanced chemilu-
minescence signals captured by a CCD camera within its linear range
using Quantity One software (Bio-Rad).
Electron microscopy immunostaining
Deeply anesthetized mice were transcardially perfusion-ﬁxed with
cold oxygenated ACSF followed by a ﬁxative containing 0.1% glutaralde-
hyde and 4% paraformaldehyde in phosphate buffer (PB; 0.1 M, pH 7.4).
The brain was removed and post-ﬁxed in 4% paraformaldehyde over-
night before washing with phosphate buffer (PB) and sectioned into
60 μm coronal sections using a vibrating microtome. Sections at the
level of CA1 in the hippocampus were selected, incubated in a solution
of 1% sodium borohydride in PBS for 20 min then washed repeatedly
in PBS. The sections were then placed in a cryoprotectant solution
(PB, 0.05 M, pH 7.4, containing 25% sucrose and 10% glycerol), frozen
at –80 °C, thawed and returned to a graded series of cryoprotectant
(100%, 70%, 50%, 30%, 0%) diluted in PBS. The sections were then
incubated in PBS containing 5% nonfat dry milk and then washed in
TRIS-buffered saline with gelatin (TBS-gelatin; 0.02 M Tris, 0.15 M
NaCl, and 1 μl/ml ﬁsh gelatin, pH 7.6) to block non-speciﬁc labeling.
Well-characterized, highly speciﬁc, primary monoclonal mouse anti-
NMDAR1 antibodies (Neuro-Mab/UC Davis, Cat# 75-272) (Cheng
et al., 2013; DeParis et al., 2012; Murata and Constantine-Paton, 2013)
were diluted in TBS-gelatin containing 1% nonfat dry milk at a 1:100
dilution. Sections were incubated at room temperature overnight,
rinsed 3 × 10 min in TBS-gelatin and incubated in the secondary anti-
body solution consisting of goat anti-mouse coupled to 1.4 nm gold
(Nanoprobes, cat# 2002) at a 1:100 dilution in TBS-gelatin containing
1% nonfat dry milk for 2 h at room temperature. The sections were
then washed in TBS-gelatin 2 × 10 min, and acetate buffer (2% aqueous
solution, pH 7.0) 1 × 10 min, followed by silver enhancement of gold
particles with the HQ silver kit (Nanoprobes Inc., Cat# 2012). Sections
were then processed for electron microscopy and ultrathin sections
were cut and collected on single slot copper grids as previously de-
scribed (Galvan et al., 2006; Gonzales et al., 2013; Hanson and Smith,
1999). As a control for the speciﬁcity of the immunolabeling, omission
of the primary antibody from the incubation solution virtually abolished
the immunostaining.
Analysis of EM material
Electron microscopic analysis was performed using a JEOL model
1011 transmission electron microscope. Blocks of tissue from the CA1
region of the hippocampus were examined and data were collected
exclusively from sections on the surface of the blocks to ensure optimal
antibody penetration into the tissue. Series of 50 random electron
micrographs of immunostained tissue were taken from each of 3 wt
and 3 PS2APP mice at 25,000×. In each of these micrographs,
immunogold-labeled elements were categorized as pre- or post-
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Fig. 1. Ro25 treatment selectively impairs LTP in PS2APP mice. (A) Basal synaptic transmission as assessed by the relationship of stimulus intensity to EPSP magnitude was normal in
PS2APP mice (n = 5 wt, 7 PS2APP). (B) LTP was induced in CA1 using 1, 2, or 3 bouts of TBS (arrows). Both wt and PS2APP mice exhibited robust LTP when recorded in the presence
of vehicle (DMSO; n=5wt, 7 PS2APP). Sample EPSPs during the baseline period and at the end of the experiment forwt and PS2APPmice are shown inset. (C) Robust LTPwith enhanced
post-tetanic potentiation (PTP)was induced in the presence of Ro25 inwtmice (n=5). Sample EPSPs during the baseline period and at the end of the experiment are shown inset. (D) LTP
induced in the presence of Ro25 was reduced in PS2APPmice (n= 8)while there was no signiﬁcant effect of Ro25 on PTP. Sample EPSPs during the baseline period and at the end of the
experiment are shown inset. (E) PTP was quantiﬁed as the average EPSP slope during the ﬁrst minute after the ﬁrst bout of TBS. Assessment by ANOVA revealed an interaction between
treatment and genotype (p b 0.05), and post hoc tests showed signiﬁcant effects of treatmentwithin wt slices (p b 0.05) and genotype within Ro25 treated slices (p b 0.05). (F) Themag-
nitude of LTPwas quantiﬁed as the average normalized EPSP slope during the ﬁnal 5min of the experiment. Assessment by ANOVA revealed a signiﬁcant effect of genotype (p b 0.05), and
post hoc tests showed signiﬁcant effects of treatment within PS2APP slices (p b 0.05) and genotype within Ro25 treated slices (p b 0.05). (G) Basal synaptic transmission was normal in
PS2APP mice in the presence of Ro25 (n = 5 wt, 8 PS2APP). All data are shown as mean ± SEM and all scale bars are 1 mV and 5 ms.
256 J.E. Hanson et al. / Neurobiology of Disease 74 (2015) 254–262synaptic structures based on their ultrastructural features (Peters and
Palay, 1996). Only gold particles located in structures that could be
clearly identiﬁed were quantiﬁed, resulting in an average of 787 ± 85gold particles quantiﬁed per animal. The average percentages of pre-
versus post-synaptic labeled elements from each group were then
calculated and statistically compared using a Student's t-test.
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Reliance of LTP on GluN2B-NMDARs in PS2APP mice
Toassess potential alterations to synaptic transmission andplasticity
that might occur in early stages of AD, we used PS2APP mice at 3–4
months of age when transgenic Aβ 1-40 and 1-42 are already detect-
able, but signiﬁcant plaque load has not yet accumulated (Ozmen
et al., 2009; Richards et al., 2003). We ﬁrst examined the input–output
(I–O) relationship in area CA1 of the hippocampus by stimulating
Schaffer collateral inputs to pyramidal neuronswith increasing stimulus
intensities and measuring ﬁeld EPSPs. These recordings showed no
change in the I–O relationship indicating unaltered AMPAR-mediated
basal synaptic transmission in PS2APPmice (Fig. 1A).When LTPwas in-
duced by 1–3 bouts of TBS under physiological recording conditions,
there was no difference between wt and PS2APP mice (Fig. 1B). Since
many previous studies have shown that GluN2B-NMDAR antagonists
rescue impairment of LTP caused by acute application of Aβ (Li et al.,
2011; Olsen and Sheng, 2012; Rammes et al., 2011; Ronicke et al.,
2011), we determinedwhether the LTP in PS2APPmice could be altered
by the selective GluN2B antagonist Ro25. To our surprise, while Ro25
did not affect wt LTP, a signiﬁcant reduction in LTP was seen in slices
from PS2APP mice in the presence of Ro25 (Fig. 1C, D, F). On the other
hand, post-tetanic potentiation (PTP) was enhanced by Ro25 in slices
from wt, but not PS2APP mice (Fig. 1C–E). The selective impairment of
LTP in PS2APP mice is unlikely due to effects of Ro25 treatment on
basal synaptic transmission because Ro25 did not result in any changes
to the I–O relationship between PS2APP and wt mice (Fig. 1G). These
results indicate that GluN2B-NMDARs provide an essential contribution
to LTP induction in PS2APP mice that is normally absent in wt mice.
Enhanced contribution of GluN2B-NMDARs during LTP induction in PS2APP
mice
The unexpected reliance of LTP on GluN2B-NMDARs in PS2APPmice
could be caused by the enhanced activation of these receptors during
LTP induction. To determine whether this is the case, we examined
the responses during the TBS that was used to induce LTP, which
consisted of 10 bursts of 5 stimuli at 100 Hz given at 200 ms intervals.
Because these responses were measured under physiological recording
conditions (including 1.3 mM extracellular Mg2+), they represent
mixed AMPAR/NMDAR EPSPs, with progressively larger contribution
from NMDARs later in the response due to alleviation of NMDAR
Mg2+ block by depolarization, and due to the longer decay time of
NMDAR EPSPs. The EPSP initial slopes during the TBS were not different
between wt and PS2APP mice and were not affected by Ro25 (data not
shown), which is consistent with the unaltered AMPAR-mediated
synaptic transmission, since the early synaptic responses are mainly
mediated by AMPARs. However, the area of the tail portion of the
averaged burst responses was signiﬁcantly reduced by Ro25 in slices
from PS2APP mice, but not in wt slices (Fig. 2). These results suggest
an enhanced contribution of GluN2B-NMDARs during TBS in PS2APP
mice which could explain the impaired LTP induction in the presence
of Ro25.
Synaptically-activated NMDARs do not contain signiﬁcant GluN2B-
NMDARs in wt or PS2APP mice
Weandothers have previously shown that GluN2B-NMDARsmake a
signiﬁcant contribution to isolated synaptic NMDAR responses in pyra-
midal neurons in 2 week-old but not 3 month-old wt mice (Hanson
et al., 2013; Harris and Pettit, 2007). Thus one possibility is that the
enhanced contribution of GluN2B-NMDARs in 3 month old PS2APP
mice could be due to a failure to undergo the normal developmental
switch from synaptic GluN2B- to GluN2A-containing NMDARs. This
would predict enhanced sensitivity of synaptic NMDAR responses toGluN2B-NMDAR antagonists. As commonly described in the literature,
synaptic NMDARs are operationally deﬁned here as being activated by
single synaptic stimulations. We ﬁrst examined the relative magnitude
of synaptic NMDAR responses by measuring the NMDA/AMPA ratio
(the initial slope of NMDAR responses over the initial slope of AMPAR
responses) and found no alteration in the PS2APP mice (Fig. 3A, B).
Taken together with the normal magnitude of AMPAR responses
(Fig. 1A), this indicates that the total magnitude of synaptic NMDAR
function is not grossly altered in PS2APP mice. We then tested the
Ro25-sensitivity of synaptic NMDARs. These experiments showed that
as in wt mice, synaptic NMDARs were not blocked by Ro25 in PS2APP
mice (Fig. 3C, D). Thus, excessive synaptic GluN2B NMDAR contribution
is not present in the PS2APP mice, arguing against a failure to undergo
the developmental switch in synaptic NMDAR subunit composition
in PS2APP mice. As an additional test of the relative abundance of
NMDAR subunits, we performed Western blot analysis of GluN1,
GluN2A, and GluN2B proteins in forebrain homogenates from PS2APP
andWTmice. These experiments showed no signiﬁcant differences be-
tween PS2APP and WT mice in levels of any of these NMDAR subunits
(Supp. Fig. 1). This provides conﬁrmation that 3 month PS2APP mice
have undergone normal developmental changes in GluN2 subunits.
Enhanced activation of GluN2B-NMDARs recruited during burst stimula-
tion in PS2APP mice
During TBS, the rapid increase in synaptic glutamate concentration
could overwhelm the capacity of glutamate transporters and result in
spill-over of glutamate and activation of glutamate receptors outside
the synapse. To isolate the NMDAR pool that is selectively activated by
burst stimulation,we ﬁrst blocked synaptic NMDARs activated by single
synaptic stimulations with the use-dependent irreversible NMDAR an-
tagonist MK-801 (Fig. 4A). After washing out MK-801, we measured
NMDAR responses elicited by burst stimulation (Fig. 4B). This protocol
revealed signiﬁcant NMDAR responses selectively recruited by burst
stimulation. We operationally deﬁne this pool of NMDARs as non-
synaptic. There was no change in the size of this NMDAR pool in
PS2APP mice compared to wt mice as assessed by normalizing the
burst-elicited NMDAR EPSP area to the single pulse-elicited area
(Fig. 4C). We were not able to directly test the Ro25 sensitivity of this
non-synaptic NMDARpool due to a substantial run-down of the isolated
NMDAR responses during repetitive burst stimuli under these recording
conditions (low Mg2+ ACSF with AMPARs blocked). However, because
run-down does not happen to mixed AMPAR/NMDAR responses to
burst stimulation recorded in regular ACSF, we assessed the Ro25-
sensitivity of burst-recruited NMDARs recorded under this condition.
The NMDAR component during burst stimulation could be estimated
by subtracting the AP5-insensitive component measured at the end of
each experiment from the mixed AMPAR/NMDAR EPSPs (Fig. 4D).
These experiments revealed only a very small reduction of the burst-
elicited NMDAR EPSP by Ro25 in wt slices, but a signiﬁcantly larger re-
duction in slices from PS2APPmice (Fig. 4E). This demonstrates a larger
contribution of GluN2B-NMDARs to the non-synaptic NMDAR pool in
PS2APP mice. Taken together with the normal synaptic NMDAR func-
tion, this suggests an increased contribution of non-synaptic GluN2B-
NMDARs during burst stimulation could underlie the reliance of LTP
on GluN2B-NMDARs in PS2APP mice.
Aberrant dependence of LTD on GluN2B NMDARs in PS2APP mice
Previous work has shown that acute application of Aβ enhances LTD
(Li et al., 2009). Thus, while LTD is normally difﬁcult to induce in brain
slices frommature mice using standard protocols, it's possible that nor-
mally subthreshold protocols could elicit LTD in 3 month PS2APP mice
due to the elevated Aβ levels. However, contrary to this hypothesis,
we did not see induction of LTD in 3 month old wt or PS2APP mice
using a subthreshold induction protocol (1 Hz stimulation in normal
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258 J.E. Hanson et al. / Neurobiology of Disease 74 (2015) 254–262ACSF; Supp. Fig. 2). While Ro25 treatment didn't change the lack of
response to the subthreshold induction protocol in either genotype,
Ro25 treatment did impair the frequency facilitation (FF) of EPSPs
seen during the onset of 1 Hz stimulation in wt mice. Interestingly, FF
was impaired in PS2APP mice compared to wt mice, which occluded
any potential effect of Ro25 (Supp. Fig. 2). This is consistent with a nor-
mal contribution of GluN2B-NMDARs to FF in wt mice that is disrupted
in PS2APP mice, potentially suggesting altered presynaptic NMDAR
function (see Discussion).
While therewasno effect of genotype or Ro25 on the response to the
subthreshold LTD induction protocol, we wanted to test if like LTP, LTD
involved an unusual dependence on GluN2B NMDARs in PS2APP mice.
To this end, we successfully induced LTD using 1 Hz stimulation in the
presence of elevated external Ca2+ (4 mM), a manipulation previously
found to allow induction of LTD in adult rodents (Norris et al., 1996).
Using this protocol, robust LTD was induced with similar magnitude in
bothwt and PS2APPmice, indicating that, aswith LTP, there is no deﬁcit
in this formof plasticity in PS2APPmice (Fig. 5A).While thedependence
of LTD on GluN2B NMDARs has been controversial and can depend on
the details of experimental conditions (Bartlett et al., 2011; Liu et al.,
2004;Morishita et al., 2007), under our experimental conditions,we ob-
served no impact of Ro25 on LTD in wt mice (Fig. 5B). However, Ro25resulted in signiﬁcant impairment of LTD in PS2APP mice (Fig. 5C, D).
This unusual dependence of LTD on GluN2B NMDARs in PS2APP mice
mirrors the results with LTP and reinforces the conclusion of aberrant
contribution of GluN2B receptors to synaptic plasticity in PS2APP mice
at this early stage of pathology.Discussion
Our study using PS2APP mice at an age with increased soluble Aβ,
but prior to signiﬁcant plaque accumulation, revealed altered and aber-
rant contributions of GluN2B-NMDARs to synaptic function and plastic-
ity in the hippocampus. Strikingly, we observed a reliance of LTP on
GluN2B-NMDARs in the PS2APPmice thatwas absent inwtmice. Exces-
sive GluN2B-NMDAR function in PS2APP mice was recruited by bursts
of stimulation but not single stimulations, implicating non-synaptic
NMDARs that aren't reached by the glutamate released during a single
stimulation. While the magnitude of LTD and ability to induce LTD
was normal in PS2APP mice, as with LTP, there was an unusual depen-
dence of LTD on of GluN2B-NMDARs. Overall our results indicate alter-
ations to GluN2B-NMDAR function in PS2APP mice that include
excessive functional contributions by a non-synaptic pool of NMDARs.
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Our ﬁndings on the contribution of GluN2B-NMDARs to long-term
plasticity are in stark contrast with the previous literature showing
that acute application of Aβ impairs LTP and enhances LTD, and that
the effects of Aβ on synaptic plasticity are mediated by GluN2B-
NMDARs (Li et al., 2009, 2011; Olsen and Sheng, 2012; Rammes et al.,
2011; Ronicke et al., 2011). Rather, our results suggest that at an early
stage of pathology in these mice with gradually accumulating Aβ
production, the system is able to maintain normal plasticity, but does
so by engaging GluN2B-NMDARs that are not normally involved in
LTP or LTD. The normal expression of LTP under standard recording
conditions is consistent with a previous study of these PS2APP mice
(Richards et al., 2003), and is a common observation in transgenic
mouse models of AD (Marchetti and Marie, 2011). The discrepancy
between impaired LTP with acute Aβ application and normal LTP in
transgenic models likely reﬂects differential impacts of a sudden eleva-
tion of Aβ concentration to an excessive level in an otherwise normal
system vs. the chronic and gradual accumulation of Aβ. We propose
that the latter situation involves adaptive changes that preserve synap-
tic plasticity, but result in reliance on abnormal mechanisms.
Precedent for dependence of synaptic plasticity on unusual mecha-
nisms comes from other studies of AD models using pharmacologicalperturbations: In the 3xTg-AD model, blockade of ryanodine receptors
unmasks excessive LTD and reduces LTP (Chakroborty et al., 2009,
2012), and in mutant PS1 KI mice, the normal enhancement of LTP by
cholinergic activation instead results in an impairment of LTP (Wang
et al., 2009). In PS2APP mice, the net impact of Aβ-induced changes
and any homeostasis is maintenance of the normal ability to induce
LTP and LTD. However, the abnormal GluN2B receptor function that is
able to support synaptic plasticity could have negative consequences
in other respects, as discussed below regarding the potential involve-
ment of GluN2B-NDMARs in cell damage. In this respect, the system
may be thought of as under an allostatic load where maintenance of
normal physiological function could come at the expense of long-term
health.
Enhanced function of GluN2B-NMDARs in a non-synaptic pool of NMDARs
in PS2APP mice
Our measurements of NMDAR function in postsynaptic neurons
implicate enhanced function of non-synaptic GluN2B-NMDARs.
Speciﬁcally, based on the way the NMDARs are activated, we identi-
ﬁed two distinct pools, 1) a pool that is activated by single synaptic
stimuli—operationally deﬁned as synaptic, and, 2) a pool that is activat-
ed selectively by burst stimuli—operationally deﬁned as non-synaptic.
Because the NMDARs in the non-synaptic pool cannot be activated by
single stimuli, they likely require glutamate spilling beyond the synaptic
cleft during bursts of activity. Our current data agree with previous
studies showing that the synaptic pool does not contain signiﬁcant
GluN2B-NMDARs in wt adult excitatory neurons (Hanson et al., 2013;
Harris and Pettit, 2007; Papouin et al., 2012), and we also did not see
a GluN2B-NMDAR contribution to the synaptic pool in PS2APP mice.
On the other hand, while there is only a very small contribution
of GluN2B-NMDARs to the non-synaptic pool in wt mice, GluN2B-
NMDARs make a signiﬁcantly larger contribution to the non-synaptic
pool in PS2APP mice.
Regarding the anatomical correlates of these receptor pools, we
propose a model in which, in addition to synaptic NMDARs within the
post-synaptic density, there are perisynaptic NMDARs which are in
the regions just outside the synapse and can be activated only during
burst stimulation in both genotypes. This non-synaptic pool is likely
perisynaptic rather than extrasynaptic, as previous studies using exoge-
nous glutamate or NMDA application in wt mice have shown a signiﬁ-
cant presence of GluN2B-NMDARs in the extrasynaptic pool (Harris
and Pettit, 2007; Papouin et al., 2012). Normally, this perisynaptic re-
ceptor pool does not contain many GluN2B-NMDARs but in PS2APP
mice their presence/activation is enhanced (Fig. 6). An excessive contri-
bution of non-synaptic GluN2B NMDARs has also been shown inmouse
models of Huntington's disease (Milnerwood et al., 2010; Okamoto
et al., 2009), indicating increased non-synaptic GluN2B function could
be a shared feature of distinct neurodegenerative diseases.
Additional potential sites of altered GluN2B NMDAR function
Some phenotypes in the PS2APP mice are suggestive of disrupted
GluN2B-NMDARs at sites in addition to postsynaptic locations on pyra-
midal neurons. For example the lack of enhancement of PTP by Ro25 in
PS2APP mice as seen in wt mice, could be due to altered function in
presynaptic excitatory inputs, or in the interneurons that gate plasticity
induction (Hanson et al., 2013). In addition, GluN2B-NMDARs are re-
quired for FF in wt mice and these GluN2B-NMDARs could be located
at presynaptic terminals. Since FF is impaired in PS2APP mice and
Ro25 has no effect on FF, this could reﬂect altered presynaptic
GluN2B-NMDARs in PS2APP mice.
To assess potential gross alterations in presynaptic NMDAR localiza-
tion, we used electron microscopy to determine the relative prevalence
of presynaptic vs. postsynaptic expression. Because pilot studies with
available NMDAR subunit-speciﬁc antibodies established conditions
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260 J.E. Hanson et al. / Neurobiology of Disease 74 (2015) 254–262for speciﬁc labeling of GluN1 in our hands, we focused on assessing local-
ization of NMDARs using immunogold labeling of these receptors. These
experiments conﬁrmed previous reports (Aoki et al., 1994; Berg et al.,
2013; Paquet and Smith, 2000; Wang and Pickel, 2000) that NMDARs
are presynaptically and postsynaptically expressed in adult wt mice,
and signiﬁcant presynaptic and postsynaptic GluN1 labeling was also
found in PS2APP mice (Supp. Fig. 3). However, although there was a
trend towards greater presynaptic localization in PS2APP mice, there
was no signiﬁcant difference in the relative localization of GluN1 labeling
in presynaptic vs. postsynaptic compartments between wt and PS2APP
mice (Supp. Fig. 3). Nonetheless, because our EM studies were limited
to GluN1 localization, a subunit present in all NMDARs, it remains possi-
ble that the fraction of presynaptic NMDARs containing GluN2B is altered
in PS2APP mice and this could contribute to the observed phenotypes.
Ultimately, future studies will be needed to explore the nature of poten-
tial presynaptic and/or interneuron NMDAR phenotypes in these mice.
Implications for therapeutic targeting of GluN2B-NMDARs in AD
Preclinical research in a variety of neurodegenerative diseasemodels
raise hopes for neuroprotection with GluN2B antagonists (Beinat et al.,2010; Gogas, 2006;Mony et al., 2009). In particular, GluN2B antagonists
protect against excitotoxic neuronal death (Liu et al., 2007) and against
Aβ-induced synapse loss (Ronicke et al., 2011). In adult rodents,
GluN2B-NMDARs are preferentially located extrasynaptically on excit-
atory neurons and extrasynaptic receptors are especially implicated in
neuronal cell death (Hardingham and Bading, 2010; Hardingham
et al., 2002). Therefore it seems likely that extrasynaptic GluN2B-
NMDARs could mediate cell damage during chronic activation that
may occur under pathological conditions such as excessive glutamate
release or reduced glutamate clearance in conditions including AD. As
discussed above our results suggest up-regulated perisynaptic GluN2B
NMDARs (non-synaptic but close enough to synapses to be activated
during burst stimulation) in PS2APP mice. This raises the possibility
that this pool of GluN2B-NMDARs could have deleterious effects on
cell health even during normal physiological activation such as the
theta burst activity that can induce LTP.
If neurodegeneration in AD in fact involves excessive activation of
non-synaptic GluN2B-NMDARs, then GluN2B-NMDAR inhibitors could
have a neuroprotective beneﬁt. On the other hand, the aberrant
GluN2B-NMDAR function in PS2APP mice appears to be playing an es-
sential role in synaptic plasticity induction. If similar GluN2B-NMDAR
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261J.E. Hanson et al. / Neurobiology of Disease 74 (2015) 254–262gain-of-functionwere to also occur as a compensatory adaptation in AD,
then potential beneﬁts of blocking GluN2B-NMDARs to prevent
excitotoxicity might be opposed by negative effects on physiological
function. In this context, we recently found that chronic in vivo
GluN2B antagonism failed to protect PS2APP mice against amyloidSingle act
Burst act
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NMDARS:
?
Fig. 6.Model of aberrant GluN2B function in PS2APPmice. Glutamate from single synaptic activa
glutamate reaching perisynaptic pools of NMDARs (light blue). Inwtmice, these perisynaptic NM
NMDARs are more sensitive to Ro25 (red). Extrasynaptic NMDARs located farther from the syn
tivity of presynaptic NMDARs (gray). While an altered physical presence of GluN2B-NMDARs
caused by impaired glutamate transport and greater spread of glutamate from the synapses duplaque-associated spine loss, and failed to prevent deﬁcits in cognitive
function (Hanson et al., 2014). Given the present results, we can't
exclude the possibility that chronic GluN2B antagonism exerted some
beneﬁcial effects by blocking extrasynaptic NMDARs, but negative
consequences of blocking perisynaptic GluN2B receptors, which appearivation
ivation
PS2APP
nsitive
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?
tions (dark blue) only reaches synaptic NMDARswhile bursts of synaptic activation lead to
DARs are generally insensitive to Ro25 (white), while in PS2APPmice, these peri-synaptic
apse are distinct from the other pools. Question marks indicate the unknown Ro25 sensi-
is depicted, the observed functional phenotypes could also result from altered activation
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262 J.E. Hanson et al. / Neurobiology of Disease 74 (2015) 254–262to be playing essential physiological roles in the PS2APPmice, may have
masked any impact of these beneﬁts on the phenotypes that were ex-
amined. Thus to the extent that this preclinical model might reﬂect
the impacts of ongoing Aβ impacts in AD patient brains, our results
raise the possibility that aberrant GluN2B-NMDAR function could
complicate efforts to achieve therapeutic beneﬁts via neuroprotection
with GluN2B-NMDAR antagonists.
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doi.org/10.1016/j.nbd.2014.11.017.Acknowledgments
The authors would like to thank William J. Meilandt for providing
PS2APP and wt brain homogenates for protein analysis and would like
to thankMorgan Sheng andmembers of the Genentech Neurophysiolo-
gy group for comments and discussion on the content of the manu-
script. YS and J-FP received ﬁnancial support from the NIH base grant
to the Yerkes Primate Center (RR00165). The authors declare no
competing ﬁnancial interests.References
Aisen, P.S., Vellas, B., Hampel, H., 2013. Moving towards early clinical trials for amyloid-
targeted therapy in Alzheimer's disease. Nat. Rev. Drug Discov. 12, 324.
Aoki, C., Venkatesan, C., Go, C.G., Mong, J.A., Dawson, T.M., 1994. Cellular and subcellular
localization of NMDA-R1 subunit immunoreactivity in the visual cortex of adult and
neonatal rats. J. Neurosci. 14, 5202–5222.
Bartlett, T.E., Lu, J.,Wang, Y.T., 2011. Slice orientation andmuscarinic acetylcholine receptor
activation determine the involvement of N-methyl D-aspartate receptor subunit
GluN2B in hippocampal area CA1 long-term depression. Mol. Brain 4, 41.
Beinat, C., Banister, S., Moussa, I., Reynolds, A.J., McErlean, C.S., Kassiou, M., 2010. Insights
into structure-activity relationships and CNS therapeutic applications of NR2B selec-
tive antagonists. Curr. Med. Chem. 17, 4166–4190.
Berg, L.K., Larsson, M., Morland, C., Gundersen, V., 2013. Pre- and postsynaptic localization
of NMDA receptor subunits at hippocampal mossy ﬁbre synapses. Neuroscience 230,
139–150.
Callaway, E., 2012. Alzheimer's drugs take a new tack. Nature 489, 13–14.
Chakroborty, S., Goussakov, I., Miller, M.B., Stutzmann, G.E., 2009. Deviant ryanodine
receptor-mediated calcium release resets synaptic homeostasis in presymptomatic
3xTg-AD mice. J. Neurosci. 29, 9458–9470.
Chakroborty, S., Kim, J., Schneider, C., Jacobson, C., Molgo, J., Stutzmann, G.E., 2012. Early
presynaptic and postsynaptic calcium signaling abnormalities mask underlying
synaptic depression in presymptomatic Alzheimer's disease mice. J. Neurosci. 32,
8341–8353.
Cheng, J., Liu, W., Duffney, L.J., Yan, Z., 2013. SNARE proteins are essential in the potenti-
ation of NMDA receptors by group II metabotropic glutamate receptors. J. Physiol.
591, 3935–3947.
Costa, R.O., Lacor, P.N., Ferreira, I.L., Resende, R., Auberson, Y.P., Klein, W.L., Oliveira, C.R.,
Rego, A.C., Pereira, C.M., 2012. Endoplasmic reticulum stress occurs downstream of
GluN2B subunit of N-methyl-d-aspartate receptor in mature hippocampal cultures
treated with amyloid-beta oligomers. Aging Cell 11, 823–833.
DeParis, S., Caprara, C., Grimm, C., 2012. Intrinsically photosensitive retinal ganglion cells
are resistant to N-methyl-D-aspartic acid excitotoxicity. Mol. Vis. 18, 2814–2827.
Ferreira, I.L., Bajouco, L.M., Mota, S.I., Auberson, Y.P., Oliveira, C.R., Rego, A.C., 2012. Amy-
loid beta peptide 1-42 disturbs intracellular calcium homeostasis through activation
of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures. Cell Calcium
51, 95–106.
Galvan, A., Kuwajima, M., Smith, Y., 2006. Glutamate and GABA receptors and trans-
porters in the basal ganglia: what does their subsynaptic localization reveal about
their function? Neuroscience 143, 351–375.
Gogas, K.R., 2006. Glutamate-based therapeutic approaches: NR2B receptor antagonists.
Curr. Opin. Pharmacol. 6, 68–74.
Gonzales, K.K., Pare, J.F., Wichmann, T., Smith, Y., 2013. GABAergic inputs from direct and
indirect striatal projection neurons onto cholinergic interneurons in the primate
putamen. J. Comp. Neurol. 521, 2502–2522.
Hansen, K.B., Ogden, K.K., Yuan, H., Traynelis, S.F., 2014. Distinct functional and pharmaco-
logical properties of Triheteromeric GluN1/GluN2A/GluN2BNMDA receptors. Neuron
81, 1084–1096.
Hanson, J.E., Smith, Y., 1999. Group I metabotropic glutamate receptors at GABAergic
synapses in monkeys. J. Neurosci. 19, 6488–6496.
Hanson, J.E., Weber, M., Meilandt, W.J., Wu, T., Luu, T., Deng, L., Shamloo, M., Sheng, M.,
Scearce-Levie, K., Zhou, Q., 2013. GluN2B antagonism affects interneurons and leads
to immediate and persistent changes in synaptic plasticity, oscillations, and behavior.
Neuropsychopharmacology 38, 1221–1233.
Hanson, J.E., Meilandt, W.J., Gogineni, A., Reynen, P., Herrington, J., Weimer, R.M., Scearce-
Levie, K., Zhou, Q., 2014. Chronic GluN2B antagonism disrupts behavior in wild-type
mice without protecting against synapse loss or memory impairment in Alzheimer's
disease mouse models. J. Neurosci. 34, 8277–8288.Hardingham,G.E., Bading, H., 2010. Synaptic versus extrasynaptic NMDA receptor signalling:
implications for neurodegenerative disorders. Nat. Rev. Neurosci. 11, 682–696.
Hardingham, G.E., Fukunaga, Y., Bading, H., 2002. Extrasynaptic NMDARs oppose synaptic
NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5,
405–414.
Harris, A.Z., Pettit, D.L., 2007. Extrasynaptic and synaptic NMDA receptors form stable and
uniform pools in rat hippocampal slices. J. Physiol. 584, 509–519.
Hatton, C.J., Paoletti, P., 2005. Modulation of triheteromeric NMDA receptors by N-
terminal domain ligands. Neuron 46, 261–274.
Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S., Stefansson, H.,
Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y.,
Bhangale, T., Graham, R.R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O.A.,
Jonsson, E.G., Palotie, A., Behrens, T.W., Magnusson, O.T., Kong, A., Thorsteinsdottir,
U., Watts, R.J., Stefansson, K., 2012. A mutation in APP protects against Alzheimer's
disease and age-related cognitive decline. Nature 488, 96–99.
Li, S., Hong, S., Shepardson, N.E., Walsh, D.M., Shankar, G.M., Selkoe, D., 2009. Soluble
oligomers of amyloid beta protein facilitate hippocampal long-term depression by
disrupting neuronal glutamate uptake. Neuron 62, 788–801.
Li, S., Jin, M., Koeglsperger, T., Shepardson, N.E., Shankar, G.M., Selkoe, D.J., 2011. Soluble
Abeta oligomers inhibit long-term potentiation through a mechanism involving
excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci.
31, 6627–6638.
Liu, L., Wong, T.P., Pozza, M.F., Lingenhoehl, K., Wang, Y., Sheng, M., Auberson, Y.P., Wang,
Y.T., 2004. Role of NMDA receptor subtypes in governing the direction of hippocam-
pal synaptic plasticity. Science 304, 1021–1024.
Liu, Y., Wong, T.P., Aarts, M., Rooyakkers, A., Liu, L., Lai, T.W.,Wu, D.C., Lu, J., Tymianski, M.,
Craig, A.M., Wang, Y.T., 2007. NMDA receptor subunits have differential roles in
mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci. 27,
2846–2857.
Marchetti, C., Marie, H., 2011. Hippocampal synaptic plasticity in Alzheimer's
disease: what have we learned so far from transgenic models? Rev. Neurosci.
22, 373–402.
Milnerwood, A.J., Gladding, C.M., Pouladi, M.A., Kaufman, A.M., Hines, R.M., Boyd, J.D., Ko,
R.W., Vasuta, O.C., Graham, R.K., Hayden, M.R., Murphy, T.H., Raymond, L.A., 2010.
Early increase in extrasynaptic NMDA receptor signaling and expression contributes
to phenotype onset in Huntington's disease mice. Neuron 65, 178–190.
Mony, L., Kew, J.N., Gunthorpe, M.J., Paoletti, P., 2009. Allosteric modulators of NR2B-
containing NMDA receptors: molecular mechanisms and therapeutic potential. Br.
J. Pharmacol. 157, 1301–1317.
Morishita, W., Lu, W., Smith, G.B., Nicoll, R.A., Bear, M.F., Malenka, R.C., 2007. Activation of
NR2B-containing NMDA receptors is not required for NMDA receptor-dependent
long-term depression. Neuropharmacology 52, 71–76.
Murata, Y., Constantine-Paton, M., 2013. Postsynaptic density scaffold SAP102 regulates
cortical synapse development through EphB and PAK signaling pathway. J. Neurosci.
33, 5040–5052.
Norris, C.M., Korol, D.L., Foster, T.C., 1996. Increased susceptibility to induction of long-term
depression and long-termpotentiation reversal during aging. J. Neurosci. 16, 5382–5392.
Okamoto, S., Pouladi, M.A., Talantova, M., Yao, D., Xia, P., Ehrnhoefer, D.E., Zaidi, R.,
Clemente, A., Kaul, M., Graham, R.K., Zhang, D., Vincent Chen, H.S., Tong, G.,
Hayden, M.R., Lipton, S.A., 2009. Balance between synaptic versus extrasynaptic
NMDA receptor activity inﬂuences inclusions and neurotoxicity ofmutant huntingtin.
Nat. Med. 15, 1407–1413.
Olsen, K.M., Sheng,M., 2012. NMDA receptors and BAX are essential for Abeta impairment
of LTP. Sci. Rep. 2, 225.
Ozmen, L., Albientz, A., Czech, C., Jacobsen, H., 2009. Expression of transgenic APPmRNA is
the key determinant for beta-amyloid deposition in PS2APP transgenic mice.
Neurodegener. Dis. 6, 29–36.
Papouin, T., Ladepeche, L., Ruel, J., Sacchi, S., Labasque, M., Hanini, M., Groc, L., Pollegioni,
L., Mothet, J.P., Oliet, S.H., 2012. Synaptic and extrasynaptic NMDA receptors are gated
by different endogenous coagonists. Cell 150, 633–646.
Paquet, M., Smith, Y., 2000. Presynaptic NMDA receptor subunit immunoreactivity in
GABAergic terminals in rat brain. J. Comp. Neurol. 423, 330–347.
Peters, A., Palay, S.L., 1996. The morphology of synapses. J. Neurocytol. 25, 687–700.
Rammes, G., Hasenjager, A., Sroka-Saidi, K., Deussing, J.M., Parsons, C.G., 2011. Therapeutic
signiﬁcance of NR2B-containing NMDA receptors andmGluR5 metabotropic glutamate
receptors inmediating the synaptotoxic effects of beta-amyloid oligomers on long-term
potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60, 982–990.
Richards, J.G., Higgins, G.A., Ouagazzal, A.M., Ozmen, L., Kew, J.N., Bohrmann, B., Malherbe,
P., Brockhaus, M., Loetscher, H., Czech, C., Huber, G., Bluethmann, H., Jacobsen, H.,
Kemp, J.A., 2003. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe,
show age-related cognitive deﬁcits associated with discrete brain amyloid deposition
and inﬂammation. J. Neurosci. 23, 8989–9003.
Ronicke, R., Mikhaylova, M., Ronicke, S., Meinhardt, J., Schroder, U.H., Fandrich, M., Reiser,
G., Kreutz, M.R., Reymann, K.G., 2011. Early neuronal dysfunction by amyloid beta
oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiol.
Aging 32, 2219–2228.
St George-Hyslop, P.H., 2000. Molecular genetics of Alzheimer's disease. Biol. Psychiatry
47, 183–199.
Wang, H., Pickel, V.M., 2000. Presence of NMDA-type glutamate receptors in cingulate
corticostriatal terminals and their postsynaptic targets. Synapse 35, 300–310.
Wang, Y., Greig, N.H., Yu, Q.S., Mattson,M.P., 2009. Presenilin-1mutation impairs choliner-
gic modulation of synaptic plasticity and suppresses NMDA currents in hippocampus
slices. Neurobiol. Aging 30, 1061–1068.
Xia, P., Chen, H.S., Zhang, D., Lipton, S.A., 2010. Memantine preferentially blocks
extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J.
Neurosci. 30, 11246–11250.
